MENLO PARK, Calif., June 10, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announces the publication of a landmark ...
Please provide your email address to receive an email when new articles are posted on . A genetic biomarker test was able to predict patients’ semaglutide treatment response after bariatric surgery.
A novel gene risk score, informed by machine learning, predicted weight-loss outcomes after Roux-en-Y gastric bypass (RYGB) surgery, a new analysis showed. The findings suggested that the MyPhenome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results